Context: Sinonasal paragangliomas have rarely been reported in the literature. They are often aggressive.
Patient: We report an original case of sinonasal paragangliomas with a tumor recurrence diagnosed 13 years after resection of the primary tumor. Somatostatin receptor scintigraphy and [18F]-fluorodeoxyglucose positron emission tomography/computed tomography were the most sensitive functional imaging techniques, and they ruled out distant metastases. Interestingly, [18F]-fluorodihydroxyphenylalanine positron emission tomography/computed tomography was negative, a feature that may be considered a sign of functional dedifferentiation. Screening for germline mutations of the SDHB, SDHC, SDHD, SDHAF2, VHL, MAX, and TMEM127 was negative.
Conclusion: The diagnosis of malignancy remains challenging at initial diagnosis, and patients should be followed during their entire lifetime.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/jc.2013-2320 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: This article reviews the presenting features, molecular characteristics, diagnosis, and management of selected skull base tumors, including meningiomas, vestibular schwannomas, pituitary neuroendocrine tumors, craniopharyngiomas, chordomas, ecchordosis physaliphora, chondrosarcomas, esthesioneuroblastomas, and paragangliomas.
Latest Developments: Skull base tumors pose a management challenge given their complex location and, as a result, the tumors and treatment can result in significant morbidity. In most cases, surgery, radiation therapy, or both yield high rates of disease control, but the use of these therapies may be limited by the surgical accessibility of these tumors and their proximity to critical structures.
Unusual presentation of a rare catecholamine-secreting sinonasal paraganglioma.
BMJ Case Rep
May 2023
Otolaryngology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Our patient is a man in his mid-20s with an atypical presentation of a catecholamine-secreting sinonasal paraganglioma. He was referred to our tertiary otolaryngology unit for persistent right infraorbital numbness. A nasoendoscopic examination demonstrated a smooth mass arising from the posterior aspect of the right middle meatus.
View Article and Find Full Text PDFTop Ten Oncocytic Head and Neck Lesions to Contemplate.
Head Neck Pathol
March 2023
Department of Pathology, Duke University, Durham, NC, USA.
Background: Oncocytes are a component of many metaplastic and neoplastic lesions throughout the head and neck area, primarily originating in salivary/seromucinous glands and the thyroid gland. In addition, other lesions can contain cells that mimic oncocytes (pseudo-oncocytes); these can be of epithelial or non-epithelial origin.
Methods: Review article.
Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa.
Acta Med Port
November 2022
Serviço de Otorrinolaringologia. Instituto Português de Oncologia Francisco Gentil. Lisboa. Portugal.
Introduction: Paragangliomas are usually benign slow-growing tumors, but they are locally invasive and can cause significant morbidity. The aim of this study was to characterize the presenting symptoms, secretory status, genetics, imaging features, treatment modalities, post-treatment complications and survival of patients with head and neck paragangliomas treated at a single institution.
Material And Methods: We retrospectively reviewed the clinical records of patients managed at our center between 1997 and 2020.
Intensity-modulated proton therapy (IMPT) versus intensity-modulated radiation therapy (IMRT) for the treatment of head and neck cancer: A dosimetric comparison.
Med Dosim
November 2021
Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
It is the goal of this study to compare the dosimetric advantages of IMPT when compared to IMRT. From January 2019 to August 2020, 25 patients were treated with intensity modulated proton therapy (IMPT) at our institution for either recurrent, metastatic, benign, or primary tumors in the head and neck region. Twenty-one patients met criteria for dosimetric analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!